Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Haemonetics (HAE) , which belongs to the Zacks Medical - Products industry.This provider blood management systems for health care providers and blood collectors has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 11.15%.For the last re ...

Company Performance - Haemonetics reported quarterly earnings of $1.24 per share, exceeding the Zacks Consensus Estimate of $1.22 per share, and up from $0.90 per share a year ago [1] - The company posted revenues of $330.6 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1%, but down from $343.29 million year-over-year [3] - The earnings surprise for this quarter was 1.64%, and Haemonetics has surpassed consensus EPS estimates two times over the last four quarters [2] Stock Performance - Haemonetics shares have declined approximately 17.7% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [4] - The current Zacks Rank for Haemonetics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.07 on revenues of $315.05 million, and for the current fiscal year, it is $4.98 on revenues of $1.32 billion [8] - The estimate revisions trend for Haemonetics is mixed, and changes in earnings expectations may occur following the recent earnings report [5][7] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [9]